Acer Therapeutics 대차 대조표 상태

재무 상태 기준 확인 0/6

Acer Therapeutics 의 총 주주 지분은 $-33.2M 이고 총 부채는 $32.1M, 이는 부채 대 자기자본 비율을 -96.4% 로 가져옵니다. 총자산과 총부채는 각각 $14.6M 및 $47.9M 입니다.

주요 정보

-96.4%

부채 비율

US$32.07m

부채

이자 보상 비율	n/a
현금	US$1.55m
주식	-US$33.25m
총 부채	US$47.89m
총 자산	US$14.65m

최근 재무 상태 업데이트

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

재무 상태 분석

단기부채: ACER 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: ACER 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: ACER 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: ACER 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: ACER 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 5.8 %의 역사적 비율로 계속 감소할 경우 ACER 의 현금 활주로는 1년 미만입니다.

Acer Therapeutics 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

Acer Therapeutics Inc. Files Form 15

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Recent updates

Acer Therapeutics Inc. Files Form 15

Acer Therapeutics Inc. Announces Executive Changes

Nasdaq to Delist the Securities of Acer Therapeutics

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc. announced delayed 10-Q filing

Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million.

Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq

Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Acer Therapeutics Inc. announced that it has received $1.5 million in funding

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021)

Insufficient new directors

Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)

Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate

Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

First half 2022 earnings released: US$0.80 loss per share (vs US$0.54 loss in 1H 2021)

RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001

Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001

Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments

Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference

Insufficient new directors

Acer Therapeutics Inc., Annual General Meeting, May 20, 2022

Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Consensus revenue estimates fall by 29%

Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

No longer forecast to breakeven

Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Consensus forecasts updated

Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting

Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors

Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA

Consensus revenue estimates increase to US$8.00m

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions

Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

New 90-day high: US$3.85

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Acer Therapeutics Inc. Announces Publication of Additional Long-Term Data from COL3A1-Positive Vascular Ehlers-Danlos Syndrome (vEDS) Patients

New 90-day low - US$2.44

New 90-day high - US$5.41

Acer Therapeutics Inc. announced that it expects to receive $0.857493 million in funding

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 2000 Dynamic Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Small Cap Completeness Index

Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Microcap Index

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표